News articles about BioMarin Pharmaceutical (NASDAQ:BMRN) have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioMarin Pharmaceutical earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.7174280516513 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- How Akcea Therapeutics’ Volanesorsen Performed in 3Q17 (finance.yahoo.com)
- How Was Incyte’s Revenue Stream in 3Q17? (finance.yahoo.com)
- Full interview with Shire CEO Flemming Ørnskov (finance.yahoo.com)
- How To Trade The JPMorgan Healthcare Conference (finance.yahoo.com)
- BioMarin CEO on hemophilia treatment success (finance.yahoo.com)
BMRN has been the topic of a number of research reports. Goldman Sachs Group reiterated a “buy” rating and issued a $129.00 price target on shares of BioMarin Pharmaceutical in a report on Friday, October 6th. Jefferies Group reiterated a “buy” rating and issued a $116.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday, September 26th. Piper Jaffray Companies reissued a “buy” rating and issued a $113.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, September 21st. BMO Capital Markets reissued a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Friday, September 15th. Finally, Stifel Nicolaus dropped their price objective on shares of BioMarin Pharmaceutical from $107.00 to $105.00 and set a “buy” rating for the company in a research note on Friday, October 27th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $112.32.
BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Thursday, October 26th. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. BioMarin Pharmaceutical had a negative net margin of 12.45% and a negative return on equity of 4.60%. The firm had revenue of $334.18 million during the quarter, compared to analysts’ expectations of $347.38 million. During the same period in the previous year, the company earned $0.02 EPS. The firm’s revenue for the quarter was up 19.4% compared to the same quarter last year. equities research analysts predict that BioMarin Pharmaceutical will post -0.64 earnings per share for the current fiscal year.
In related news, insider Henry J. Fuchs sold 15,000 shares of BioMarin Pharmaceutical stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $89.23, for a total transaction of $1,338,450.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock in a transaction dated Saturday, December 29th. The stock was sold at an average price of $89.61, for a total transaction of $896,100.00. Following the transaction, the chief executive officer now directly owns 226,494 shares of the company’s stock, valued at $20,296,127.34. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 60,750 shares of company stock valued at $5,439,788. 1.85% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “BioMarin Pharmaceutical (BMRN) Given Coverage Optimism Score of 0.19” was first published by Markets Daily and is the sole property of of Markets Daily. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.themarketsdaily.com/2018/01/12/biomarin-pharmaceutical-bmrn-given-coverage-optimism-score-of-0-19.html.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.